Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy.
HSV-TK
antigen-presenting cell
c-Myc
cancer immunotherapy
granulocyte-macrophage colony-stimulating factor
iCasp9
induced pluripotent stem cell
suicide gene
Journal
Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857
Informations de publication
Date de publication:
11 Jun 2021
11 Jun 2021
Historique:
received:
22
09
2020
accepted:
02
03
2021
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
6
4
2021
Statut:
epublish
Résumé
The tumorigenicity and toxicity of induced pluripotent stem cells (iPSCs) and their derivatives are major safety concerns in their clinical application. Recently, we developed granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing proliferating myeloid cells (GM-pMCs) from mouse iPSCs as a source of unlimited antigen-presenting cells for use in cancer immunotherapy. As GM-pMCs are generated by introducing
Identifiants
pubmed: 33816647
doi: 10.1016/j.omtm.2021.03.002
pii: S2329-0501(21)00041-3
pmc: PMC7994724
doi:
Types de publication
Journal Article
Langues
eng
Pagination
171-179Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
Y.U. received research funding from AGC, Inc., Japan. The remaining authors declare no competing interests.
Références
Oncoimmunology. 2020 Sep 6;9(1):1814620
pubmed: 33457097
Cell Stem Cell. 2009 Apr 3;4(4):289-300
pubmed: 19341619
Cancer Gene Ther. 2019 Feb;26(1-2):11-16
pubmed: 29955091
Stem Cells Transl Med. 2019 Mar;8(3):260-270
pubmed: 30485733
Cell Rep. 2019 Oct 1;29(1):162-175.e9
pubmed: 31577946
Biomaterials. 2012 Oct;33(29):7261-71
pubmed: 22795541
Biol Blood Marrow Transplant. 2007 Aug;13(8):913-24
pubmed: 17640595
Immunol Rev. 2014 Mar;258(1):12-29
pubmed: 24517423
Nat Rev Cancer. 2001 Nov;1(2):130-41
pubmed: 11905804
Mol Ther. 2007 Apr;15(4):834-40
pubmed: 17327829
J Leukoc Biol. 2008 Feb;83(2):393-400
pubmed: 17965335
Cell Stem Cell. 2018 Dec 6;23(6):850-858.e4
pubmed: 30449714
Mol Cancer. 2019 Aug 20;18(1):125
pubmed: 31429760
J Immunol. 2004 Jan 15;172(2):776-86
pubmed: 14707047
Mol Ther Methods Clin Dev. 2014 Nov 12;1:14053
pubmed: 26052521
Clin Cancer Res. 2008 Aug 15;14(16):5000-5
pubmed: 18698017
Nat Rev Immunol. 2012 Jul 13;12(8):557-69
pubmed: 22790179
Int J Mol Sci. 2020 Apr 03;21(7):
pubmed: 32260086
Mol Ther. 2015 Sep;23(9):1475-85
pubmed: 26022733
iScience. 2019 Dec 20;22:409-422
pubmed: 31821946
Lancet Oncol. 2013 Aug;14(9):823-33
pubmed: 23850491
Lancet Oncol. 2014 Jun;15(7):e257-67
pubmed: 24872109
Front Immunol. 2018 Jan 08;8:1935
pubmed: 29358940
Trends Immunol. 2017 Aug;38(8):577-593
pubmed: 28610825
Stem Cells Transl Med. 2017 Feb;6(2):382-393
pubmed: 28191782
Immunity. 2013 Jul 25;39(1):38-48
pubmed: 23890062
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
Blood. 2007 Jun 1;109(11):4708-15
pubmed: 17327417
Clin Cancer Res. 2016 Apr 15;22(8):1897-906
pubmed: 27084743
Nat Rev Drug Discov. 2017 Feb;16(2):115-130
pubmed: 27980341
Mol Ther Oncolytics. 2016 Apr 20;3:16011
pubmed: 27626062
J Clin Oncol. 2008 Nov 10;26(32):5198-203
pubmed: 18824702
Gene Ther. 2008 Nov;15(21):1411-23
pubmed: 18496571
J Clin Oncol. 2009 Sep 20;27(27):4481-6
pubmed: 19687333
Cancer Lett. 2017 Dec 28;411:182-190
pubmed: 28947140
Nat Rev Cancer. 2008 Jan;8(1):61-70
pubmed: 18075512
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):E3281-90
pubmed: 23918355
Lancet Oncol. 2013 Oct;14(11):e447-e456
pubmed: 24079872
Cancer Immunol Res. 2015 Jun;3(6):668-77
pubmed: 25672396
Mol Ther Methods Clin Dev. 2016 Mar 09;3:16003
pubmed: 27626039
N Engl J Med. 2011 Nov 3;365(18):1673-83
pubmed: 22047558
J Biomed Biotechnol. 2011;2011:539748
pubmed: 21331358
Stem Cells Transl Med. 2020 Nov;9(11):1378-1388
pubmed: 32662231
Nat Protoc. 2011 Mar;6(3):296-313
pubmed: 21372811
Blood. 2003 May 1;101(9):3501-8
pubmed: 12406878
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
Stem Cells. 2007 Nov;25(11):2720-9
pubmed: 17690179
Lancet Oncol. 2009 May;10(5):489-500
pubmed: 19345145
Oncotarget. 2015 Aug 28;6(25):21137-47
pubmed: 26023798
Exp Hematol. 2007 Jun;35(6):957-66
pubmed: 17533050
Mol Cancer. 2011 Apr 06;10:35
pubmed: 21470426